Butoconazole nitrate, an azole antifungal, is indicated for the local treatment of vulvovaginal candidiasis (infections caused by Candida). Azole antifungals inhibit a CYP450 enzyme which catalyses the synthesis of ergosterol, the primary sterol in the fungal cell membrane. This inhibition causes an accumulation of methylsterols which inhibit cell membrane formation, ultimately preventing fungal growth.
Perrigo is working with KV Pharmaceutical to launch this product by the end of 2012.
For more information call (866) 634-9120 or visit www.perrigo.com.